Last reviewed · How we verify
Tirosin Kinase Inhibitors
At a glance
| Generic name | Tirosin Kinase Inhibitors |
|---|---|
| Also known as | TKI |
| Sponsor | Spanish Lung Cancer Group |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia
- T790M Mutation Testing in Blood by Different Methodologies
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tirosin Kinase Inhibitors CI brief — competitive landscape report
- Tirosin Kinase Inhibitors updates RSS · CI watch RSS
- Spanish Lung Cancer Group portfolio CI